<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7764221/table_3" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 3</label>
  <p>Main studies in relation to thymoquinone (TQ) and 
   <i>Nigella sativa</i> (NS) of interest in periodontal disease. 
  </p>
 </caption>
 <thead>
  <tr>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-0-.">Compound</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-1-.">Study Type</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-2-.">Sample Studied, n</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-3-.">Adminitration (Dosage, Frecuency and Duration)</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-4-.">Main Effects</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-5-.">Reference</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic healthy periodontitis male and female patients with at least 2 periodontally involved sites (≥5 mm), n = 20</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2% TQ topical (intra-pocket) oral gel; repeated every week beginning from baseline up to 4 weeks.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant decrease in PPD, GCF-ALP levels and rise in CAL 
    <br/>Antibacterial effect of TQ against against 
    <i>P. gingivalis</i>, 
    <i>A. actinomycetemcomitans</i> and 
    <i>P. intermedia</i>
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B62-antioxidants-09-01260" ref-type="bibr">62</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic healthy chronic periodontitis male and female patients (25–58 years) with at least 10 periodontally involved sites (≥5 mm), n = 48</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1% TQ topical (intra-pocket) oral gel; immediately after accomplishment of SRP. The gel was applied again after 48 h and the gel applied sites were covered with a periodontal pack for 7 days. Results were recorded at baseline and at weeks 4 and 12 after treatment.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant improvement in PI, GI, PPD, CAL 
    <br/>Significant improvement in the levels of IL-1β and TAOC 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B63-antioxidants-09-01260" ref-type="bibr">63</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic healthy chronic periodontitis male patients (35–56 years) with at least 4 periodontally involved sites (≥5 mm), n = 12</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biodegradable chitosan subgingival periodontal chip with integrated 0.25 mg TQ with second chip insertion at day 14. Results were recorded at day 14 and 60 of the trial.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant gains in CAL</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B65-antioxidants-09-01260" ref-type="bibr">65</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Animal</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male Wistar rats with ligature-induced periodontal inflammation (300 ± 10 g), n = 8</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic intragastric (10 mg/kg, daily for 11 days)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant reduction of alveolar bone loss and inflammatory cell infiltration 
    <br/>Maintenance of osteoblastic activity 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B66-antioxidants-09-01260" ref-type="bibr">66</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Animal</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male Fisher rats (21 days old), n = 16</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2% TQ topical oral gel and systemic administration in drinking water. The oral gel was applied daily over gingiva and the drinking water was changed 3 times a week. Outcomes were measured at day 1, 7 and 35.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant reduction in BOP, PI in rats that received TQ as oral gel or systemically 
    <br/>Less evident signs of gingivitis and periodontitis histologically in TQ treated rats 
    <br/>Antibacterial effect of TQ against subgingival bacteria 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B64-antioxidants-09-01260" ref-type="bibr">64</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacterial strains of 
    <i>Fusobacterium nucleatum</i> ATCC25586 (FN), 
    <i>Actinomyces naeslundii</i> X600 (AN) and 
    <i>Streptococcus mitis</i> ATCC 903 ( 
    <i>SM</i>) 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1%, 0.01% and 0.05% TQ reagents were added to bacterial formed biofilms and incubated for 24 h and for 30 min</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibitory effect of 0.1% TQ on 
    <i>FN</i>-containing biofilm 
    <br/>Significantly decreased biofilm formation of 
    <i>FN</i> pretreated with 0.01% TQ 
    <br/>Significant cleansing effect of 0.01% and 0.05% TQ on 
    <i>FN</i>-containing biofilm 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B67-antioxidants-09-01260" ref-type="bibr">67</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacterial strains of 
    <i>Fusobacterium nucleatum</i> ATCC 25586 (FN) and 
    <i>Porphyromonas gingivalis</i> A7436 (PG) 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10% TQ reagent was added to bacterial formed biofilms and incubated for 48 h</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The minimum inhibitory concentration (MIC) of TQ was 12.5 and 1.56 μg/mL in FN and PG, respectively. 
    <br/>Sub-MIC concentrations of TQ prevented biofilm formation, hemolysis activities and H2S generation of 
    <i>FN</i> and 
    <i>PG</i> and 
    <br/>TQ disintegrated bacterial membranes and reduced the expression of virulence factors in 
    <i>FN</i> and 
    <i>PG</i>
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B68-antioxidants-09-01260" ref-type="bibr">68</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
    <i>NS</i>
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Twelve gram-positive and eleven Gram-negative bacterial strains, including 
    <i>Staphylococcus aureus</i>, 
    <i>Enterococcus faecalis, Staphylococcus epidermidis</i>, 
    <i>Porphyromonas</i> sp., 
    <i>Proteus</i> sp., 
    <i>Streptococcus pneumoniae</i>, 
    <i>Klebsiella pneumoniae</i>, 
    <i>Acinetobacter baumannii/calcoaceticus</i> and 
    <i>Veillonella</i> sp., isolated from supra- and subgingival plaque of periodontal patients 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methanol and essential oil solutions of 
    <i>NS</i> 2% ±0.35 dry extract were added to the isolated bacteria in microdilution test and Agar well diffusion assay 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibacterial effect of the essential oil and less efficiency of the methanol against all tested bacteria</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B69-antioxidants-09-01260" ref-type="bibr">69</a>] 
   </td>
  </tr>
 </tbody>
 <tfoot>
  <p class="fn" charset="fn">
   <p>PPD: Probing pocket depth; GCF-ALP: Gingival crevicular fluid alkaline phosphatase; CAL: Clinical attachment level; SRP: Scaling and root planning; PI: Plaque index; GI: Gingival index; TAOC: Total antioxidant capacity; FN: Fusobacterium nucleatum; AN: Actinomyces naeslundii; PG: Porphyromonas gingivalis.</p>
  </p>
 </tfoot>
</table>
